Acerta Pharma B.V. (A Member Of The Astrazeneca Group)

Acerta Pharma B.V. (A Member Of The Astrazeneca Group) company information, Employees & Contact Information

Acerta Pharma is a European R&D centre of the AstraZeneca group dedicated to the discovery and development of novel innovative drugs for the treatment of haematological malignancies. The company began operations in 2013 with the vision of combining cutting edge science, unique covalent technology, and an experienced, dedicated team in order to deliver novel targeted therapies for patients with cancer. In 2016 AstraZeneca took a majority stake in the company and Acerta Pharma was fully acquired by AstraZeneca in 2021. As part of the significant expansion of our research activities in the Netherlands, we are in the process of building a new research centre in Pivot Park with state-of-the-art research laboratories for more than 140 researchers in Oss, the Netherlands. We are working to develop new treatment options for patients with specific types of blood cancer. Together with our R&D colleagues of AstraZeneca in Gaithersburg, San Francisco, Boston (US), Gothenburg (SE) and Cambridge (UK) we are committed to innovative drug discovery and development, especially in the field of haematological oncology.

Company Details

Employees
151
Founded
-
Address
Kloosterstraat 9, Oss,5349 Ab,netherlands
Phone
650-591-2800
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
OSS
Looking for a particular Acerta Pharma B.V. (A Member Of The Astrazeneca Group) employee's phone or email?

Acerta Pharma B.v. (A Member Of The Astrazeneca Group) Questions

News

EHA19: AstraZeneca's Calquence cuts risk of disease progression, death by 69% in chronic lymphocytic leukaemia study - FirstWord Pharma

EHA19: AstraZeneca's Calquence cuts risk of disease progression, death by 69% in chronic lymphocytic leukaemia study FirstWord Pharma

AstraZeneca buy Acerta faked cancer drug data, company admits - Fierce Biotech

AstraZeneca buy Acerta faked cancer drug data, company admits Fierce Biotech

AstraZeneca to Buy Stake in Acerta Pharma - The Wall Street Journal

AstraZeneca to Buy Stake in Acerta Pharma The Wall Street Journal

AstraZeneca to acquire 55% stake in Acerta Pharma - European Pharmaceutical Review

AstraZeneca to acquire 55% stake in Acerta Pharma European Pharmaceutical Review

AstraZeneca buys most of Acerta for $4 billion to add cancer drug - Reuters

AstraZeneca buys most of Acerta for $4 billion to add cancer drug Reuters

Bay Area Acerta Pharma Falsified Early Data on a Cancer Compound, Now in Clinical Trials - BioSpace

Bay Area Acerta Pharma Falsified Early Data on a Cancer Compound, Now in Clinical Trials BioSpace

AstraZeneca adds 55% Acerta Pharma stake to swath of deals - Financial Times

AstraZeneca adds 55% Acerta Pharma stake to swath of deals Financial Times

AstraZeneca to Acquire Majority Stake in Acerta Pharma (Published 2015) - The New York Times

AstraZeneca to Acquire Majority Stake in Acerta Pharma (Published 2015) The New York Times

Fierce JPM Week: AstraZeneca cancer R&D head marks Imfinzi as 'core backbone' of oncology strategy with the right combo—including treme - Fierce Pharma

Fierce JPM Week: AstraZeneca cancer R&D head marks Imfinzi as 'core backbone' of oncology strategy with the right combo—including treme Fierce Pharma

AstraZeneca to strengthen presence in California with new South San Francisco location - AstraZeneca US

AstraZeneca to strengthen presence in California with new South San Francisco location AstraZeneca US

UPDATE: AstraZeneca buys 55% stake in Acerta for $4 billion - BioPharma Dive

UPDATE: AstraZeneca buys 55% stake in Acerta for $4 billion BioPharma Dive

Dave Johnson Joins Biosplice Therapeutics Board of Directors - citybiz

Dave Johnson Joins Biosplice Therapeutics Board of Directors citybiz

Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL - PR Newswire

Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL PR Newswire

Meet the Peninsula company that just nailed its 1st cancer drug win - The Business Journals

Meet the Peninsula company that just nailed its 1st cancer drug win The Business Journals

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma - Nature

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma Nature

Book Review: Behind Wall Street’s Huge Gamble on Cancer Drugs - Gavi, the Vaccine Alliance

Book Review: Behind Wall Street’s Huge Gamble on Cancer Drugs Gavi, the Vaccine Alliance

AstraZeneca's Q1 sales top forecasts, boosted by cancer drugs - FirstWord Pharma

AstraZeneca's Q1 sales top forecasts, boosted by cancer drugs FirstWord Pharma

AstraZeneca in Talks to Buy Cancer Drug Developer Acerta Pharma - The Wall Street Journal

AstraZeneca in Talks to Buy Cancer Drug Developer Acerta Pharma The Wall Street Journal

AstraZeneca raising profile in Bay Area - BioPharma Dive

AstraZeneca raising profile in Bay Area BioPharma Dive

AstraZeneca's Calquence garners FDA approval for mantle cell lymphoma - FirstWord Pharma

AstraZeneca's Calquence garners FDA approval for mantle cell lymphoma FirstWord Pharma

The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market - MedPage Today

The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market MedPage Today

Can AstraZeneca's Calquence really siphon share from AbbVie and J&J's Imbruvica? - Fierce Pharma

Can AstraZeneca's Calquence really siphon share from AbbVie and J&J's Imbruvica? Fierce Pharma

Five Biggest Drug Face-Offs in Pharma History - BioSpace

Five Biggest Drug Face-Offs in Pharma History BioSpace

US FDA APPROVES ASTRAZENECA'S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA - PR Newswire

US FDA APPROVES ASTRAZENECA'S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA PR Newswire

AstraZeneca to scoop up biotech TeneoTwo for up to $1.27 billion - drugdiscoverytrends.com

AstraZeneca to scoop up biotech TeneoTwo for up to $1.27 billion drugdiscoverytrends.com

VelosBio Raises $137 Million Series B Funding For Cancer Drug Development - San Diego Business Journal

VelosBio Raises $137 Million Series B Funding For Cancer Drug Development San Diego Business Journal

“For Blood and Money” charts a race to develop a blockbuster drug - The Economist

“For Blood and Money” charts a race to develop a blockbuster drug The Economist

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer - citybiz

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer citybiz

BioGeneration Ventures closes 4th fund, with $170M in tow for early European biotechs - Fierce Biotech

BioGeneration Ventures closes 4th fund, with $170M in tow for early European biotechs Fierce Biotech

Riled by AZ CEO's $12M package, investors push pay overhaul - Fierce Pharma

Riled by AZ CEO's $12M package, investors push pay overhaul Fierce Pharma

How Does Venture Capital Shape Biotech Innovation? - promarket.org

How Does Venture Capital Shape Biotech Innovation? promarket.org

New Israeli Drug That Treats Prostate Cancer Approved In Mexico - i24NEWS

New Israeli Drug That Treats Prostate Cancer Approved In Mexico i24NEWS

Top Acerta Pharma B.V. (A Member Of The Astrazeneca Group) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant